Full-Time

Lead Clinical Laboratory Scientist-Flow Cytometry

Deadline 3/19/27
Sysmex

Sysmex

1,001-5,000 employees

Manufactures automated hematology analyzers and diagnostics

Compensation Overview

$85.1k - $95.8k/yr

Itasca, IL, USA

In Person

Bachelor's

Category
Medical, Clinical & Veterinary (1)
Required Skills
Word/Pages/Docs
Quality Assurance (QA)
Excel/Numbers/Sheets

Get referred to Sysmex

See people who can refer or advise you

Requirements
  • A bachelor's degree in one of the biological, chemical or medical sciences is required.
  • Certification as a Certified Histocompatibility Technologist or Certified Histocompatibility Specialist issued by the American College of Histocompatibility and Immunogenetics is required, or the ability to obtain certification within 18 months of hire or promotion.
  • A minimum of 2 years of experience in high-complexity testing in histocompatibility, immunology, infectious disease or virology is required.
  • Technical competency in at least three clinical testing areas, including infectious disease, HLA typing, crossmatching, and HLA antibody testing, is required.
  • Basic skills in Excel and Word are required.
  • Proficiency with laboratory software systems is required.
  • Familiarity with procedures for quality control of reagents and maintenance of equipment is required.
  • The ability to learn and apply new laboratory testing methods, processes, and equipment is required.
  • The ability to manage and perform multiple tests simultaneously in a timely and organized manner is required.
  • The ability to prioritize tasks to meet deadlines and laboratory objectives is required.
  • Attention to detail is required to conduct and interpret laboratory tests.
  • Analytical ability is required to evaluate test results and identify atypical results.
  • The ability to lift and move 30 pounds is required.
  • The ability to communicate information effectively, clearly, and accurately is required.
  • The ability to perform precision tasks, such as conducting tests and repairing equipment, is required.
  • Visual acuity is required to read and record test results and conduct equipment maintenance.
  • The employee must work outside normal business hours, including weekends, evenings, and holidays.
  • The employee must carry a personal cell phone and remain accessible outside regular business hours.
Responsibilities
  • Perform high-complexity laboratory testing using established methodologies, including molecular HLA typing, flow cytometry, genetic analysis, HLA antibody screening, ABO typing, and infectious disease testing.
  • Serve as section lead by providing oversight and guidance for designated laboratory areas.
  • Serve as the final reviewer and sign off clinical cases covering technical, quality, billing, and other designated testing aspects.
  • Document test results and pertinent information, interpret complex reaction patterns, and identify probable causes of irregular or atypical results.
  • Compile and prepare section quality assurance reports.
  • Lead process improvement initiatives.
  • Communicate results to internal and external customers, including clinicians, transplant coordinators, and other organ and tissue procurement organization personnel.
  • Enter, retrieve, and transmit test data into laboratory information systems.
  • Assist laboratory staff with testing procedures, quality controls, and standard operating protocols.
  • Provide instruction and guidance to new employees in testing procedures, quality controls, and standard operating protocols.
  • Perform laboratory employee competency assessments as required.
  • Provide laboratory employee support, direction, and management as requested by laboratory management.
  • Assist with personnel management, including one-on-one meetings, performance evaluations, coaching, and disciplinary actions.
  • Assist with the development, validation, and implementation of new or revised procedures and protocols.
  • Preserve donor cells and serum samples for potential future testing.
  • Process blood samples received from patients waiting for a transplant.
  • Prepare reagents required for analysis and ensure that reagents are available and usable.
  • Set up and monitor equipment required to perform tests.
  • Maintain preventive maintenance schedules for assigned equipment.
  • Perform minor equipment repairs, including adjustments and calibration.
  • Maintain quality control records and logs, and prepare, record, and store data for future reference.
  • Monitor supply levels to ensure adequate supplies are maintained.
  • Maintain cleanliness and organization of the work area in accordance with safety standards.
  • Serve as an on-call, off-hours technical consultant for laboratory employees.
  • Work with laboratory leadership to develop, plan, implement, monitor, and assess laboratory quality assurance and performance improvement programs.
  • Identify non-conformances and deficiencies and manage the corrective action process.
  • Promote quality assurance and performance improvement throughout the laboratory.
  • Work with laboratory leadership to ensure compliance with pertinent regulatory agencies, including CMS/CLIA, FDA, UNOS, ASHI, and CAP.
  • Determine, track, trend, and report relevant quality metrics, including turnaround times, error rates, and customer satisfaction scores.
  • Assist laboratory leadership with preparation for internal and external audits and inspections and with follow-up responses and corrective actions.
  • Complete continuing education.

Sysmex designs and sells instruments and reagents for in-vitro diagnostics, with a focus on automated hematology analyzers that count and evaluate blood cells, enabling clinical decision-making. Over time, it expanded into genetics through the acquisition of Oxford Gene Technology and into rapid antimicrobial testing with Astrego, broadening its diagnostic portfolio. The company differentiates itself by growing through acquisitions to build a diverse, global product line and by maintaining a strong brand presence in workflows for hematology, genetics, and infectious disease testing across more than 190 countries. Its goal is to provide essential, reliable diagnostic tools that support healthcare worldwide, helping clinicians diagnose and treat diseases faster and more accurately.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Kobe, Japan

Founded

1968

Get referred to Sysmex

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Sysmex launched XR-Series in May 2026, upgrading installed XN customers without workflow disruption.
  • Sysmex launched CN-9000 in January 2026, reaching 1,000 samples hourly for high-volume labs.
  • Sysmex added RIKEN GENESIS and Megakaryon stakes, expanding genetics and regenerative medicine platforms.

What critics are saying

  • Sysmex reported FY2026 sales of ¥500.0 billion and profit of ¥35.5 billion, down sharply.
  • Sysmex faced a JFTC Antimonopoly Act probe; compliance failures threaten fines and contracts in 2026.
  • China procurement pressure and reagent supply disruptions hit revenue fast; prolonged weakness threatens global leadership.

What makes Sysmex unique

  • Sysmex owns the XR-Series and CN-9000, embedding sticky workflows into core laboratories.
  • Sysmex sells modular hematology and hemostasis systems across 190 countries, supporting global standardization.
  • Sysmex pairs instruments with proprietary reagents and service teams, locking in recurring revenue.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Time Off

Parental Leave

Bereavement Leave

401(k) Retirement Plan

401(k) Company Match

Annual Incentive Bonus

Growth & Insights and Company News

Headcount

6 month growth

32%

1 year growth

32%

2 year growth

32%
Manufacturing & Logistics Online
May 29th, 2026
Sysmex America unveils next generation XR-Series to streamline hematology testing.

Sysmex America unveils next generation XR-Series to streamline hematology testing. Sysmex America introduces the XR-Series, featuring the XR-10 Automated Hematology Module, designed to deliver fast, reliable results with improved analytics and workflow efficiency for busy laboratories. May 29, 2026 Sysmex America, Inc. has unveiled the next generation XR-Series, a hematology solution designed to help busy laboratories deliver fast, reliable results while maintaining efficient workflows. At the center of the new system is the XR-10 Automated Hematology Module, built for high-complexity laboratories that need speed, consistency and dependable performance. The next-generation XR-Series builds on the trusted capabilities of the popular XN-Series, adding higher throughput, enhanced analytics and complementary solutions that streamline daily lab operations. Enhancements to the WBC differential reagent, combined with innovative 3D scattergram visualization and the optional WPC channel on the XR-20 Automated Hematology Module, provide valuable insights that support result interpretation, improve flagging accuracy and increase confidence in results. The new reagent formulation allows greater separation of cell clusters in the WDF scattergram without sacrificing accurate WBC differential flagging. For existing Sysmex hematology users, the transition is designed to be seamless. The system maintains the familiar operation and user interface of the widely adopted XN-Series while preserving its modular design. The XR-9000 configuration for high-volume labs also integrates with complementary products that help automate routine steps and increase efficiency, supporting smoother workflows across the laboratory. The new frontier of point-of-care testing. Discover how next-generation handheld diagnostics are changing medicine at the speed of care. Get the Free eBook

PR Newswire
May 28th, 2026
Sysmex America launches XR-Series hematology solution for clinical laboratories

Sysmex America has launched the next generation XR-Series hematology solution for clinical laboratories. The system centres on the XR-10 Automated Hematology Module, designed for high-complexity labs requiring speed and consistency. Building on the XN-Series, the new platform offers higher throughput, enhanced analytics and streamlined workflows. The XR-20 module features an optional WPC channel and improved WBC differential reagent with 3D scattergram visualisation for better result interpretation and flagging accuracy. The system maintains the familiar XN-Series interface and modular design, enabling smooth transitions for existing users. The high-volume XR-9000 configuration integrates with complementary automation products. Sysmex America, based in Chicago, is the Americas regional affiliate of Kobe-based Sysmex Corporation, offering diagnostic solutions across hematology, hemostasis, urinalysis, flow cytometry and informatics.

Sysmex
May 28th, 2026
Sysmex America introduces next generation xr-series(tm) hematology solution for clinical laboratories.

Sysmex America introduces next generation xr-series(tm) hematology solution for clinical laboratories. Chicago - May 28, 2026 - Sysmex America, Inc., a leading diagnostic solutions company offering hematology, hemostasis, urinalysis, flow cytometry and informatic solutions, has introduced the next generation XR-Series, a hematology solution designed to help busy laboratories deliver fast, reliable results while maintaining efficient workflows. At the center of the new system is the XR-10 Automated Hematology Module, built for high-complexity laboratories that need speed, consistency and dependable performance. The next-generation XR-Series builds on the trusted capabilities of the popular XN-Series(TM), adding higher throughput, enhanced analytics and complementary solutions that streamline daily lab operations. "The XR-Series reflects our commitment to helping laboratories work smarter without disrupting the workflows they depend on," said Dan Zortman, CEO of Sysmex America. "By combining proven reliability, advanced analytics and the support of our award-winning service teams, the XR-Series analyzers help laboratories deliver the accuracy and precision clinicians rely on for outstanding patient care." Enhancements to the WBC differential reagent, combined with innovative 3D scattergram visualization and the optional WPC channel on the XR-20 Automated Hematology Module, provide valuable insights that support result interpretation, improve flagging accuracy and increase confidence in results. The new reagent formulation allows greater separation of cell clusters in the WDF scattergram without sacrificing accurate WBC differential flagging. For existing Sysmex hematology users, the transition is designed to be seamless. The system maintains the familiar operation and user interface of the widely adopted XN-Series while preserving its modular design. This allows laboratories to quickly adopt the new system while benefiting from improved performance. The XR-9000(TM) configuration for high-volume labs also integrates with complementary products that help automate routine steps and increase efficiency, supporting smoother workflows across the laboratory. The next generation XR-Series is backed by Sysmex America's award-winning service and support teams, helping laboratories keep systems running smoothly and maintain confidence in their results. To learn more about the XR-Series and Sysmex America's full portfolio of hematology products, visit www.sysmex.com. About Sysmex America The combination of Sysmex America's new testing methods and innovative hematology, hemostasis, urinalysis, flow cytometry and informatic systems are transforming the future of healthcare and contributing to healthier lives. As Americas regional affiliate of Kobe, Japan-based Sysmex Corporation - a trusted global leader respected for optimizing the efficiency, operations and financial performance of clinical laboratories - it offers diagnostic products that equip patients and the healthcare professionals who treat them with the information needed to make decisions with greater trust and confidence. Forbes magazine named Sysmex one of the most innovative companies in the healthcare equipment and services category, and the Center for Companies That Care named Sysmex America to its "Honor Roll." Learn more about Sysmex America at www.sysmex.com/Sysmex America, Inc. Media Contact Julie Baron [email protected] 847-525-3043

Sysmex Corporation
Mar 5th, 2026
Sysmex Acquires Additional Shares in RIKEN GENESIS and Converts Company to a Subsidiary

This section provides Sysmex’s most recent news releases related to IR information, products and support, research and development, corporate information and other notifications.

Sysmex Corporation
Jan 22nd, 2026
Launch of "CN(TM)-9000 Automated Hemostasis Solution" for Large-Scale Laboratories in North America - Supporting the Optimization of Laboratory Workflow - (Sysmex America)

Launch of "CN(TM)-9000 Automated Hemostasis Solution" for large-scale laboratories in North America - supporting the optimization of laboratory workflow - (Sysmex America). Sysmex America, Inc., a Sysmex Group company, has launched the "CN(TM)-9000 Automated Hemostasis Solution" as a new addition to the CN-Series for hemostasis testing in the North American market. This product supports further automation and increased efficiency in testing operations at large hospitals and testing centers with high test volumes. In addition to standalone operation, the CN(TM)-9000 is compatible with Total Laboratory Automation (TLA) lines, enabling flexible system configurations tailored to the size and operational needs of each laboratory. For further details, please refer to Sysmex America's press release. Going forward, Sysmex will continue to work to further enhance the value of hemostasis through product development and services that address the increasingly varied and sophisticated needs of medical settings, thereby contributing to improved patient outcomes. * The purpose of this news is to communicate its business activities to its stakeholders. It may or may not include information about Sysmex's products or their research and development, but this is not intended for promotion, advertising, or medical advice. The information contained in this press release is current as of the date of the announcement but may be subject to change without prior notice.